SciHub
文献互助
期刊查询
一搜即达
科研导航
交流社区
登录
注册
发布
文献
求助
首页
我的求助
捐赠本站
已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!
小新麻麻
Lv3
320 积分
2022-02-10 加入
最近求助
最近应助
互助留言
A phase II, single-arm, open label, Simon two-stage study of pembrolizumab in patients with metastatic HER2-negative breast cancer: Evaluation of impact of germline variants in APOBEC3B (AUROR)
6天前
已完结
Cancer incidence and mortality in China, 2022
19天前
已完结
Current FIGO staging for cancer of the vagina, fallopian tube, ovary, and gestational trophoblastic neoplasia
1个月前
已完结
Cancer incidence and mortality in China, 2022
2个月前
已完结
Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study
2个月前
已完结
Phase II trial of efficacy, safety and biomarker analysis of sintilimab plus anlotinib for patients with recurrent or advanced endometrial cancer
3个月前
已完结
A phase II trial of lenvatinib in patients with advanced or recurrent endometrial cancer: Angiopoietin-2 as a predictive marker for clinical outcomes
5个月前
已关闭
How to diagnose and manage neurological toxicities of immune checkpoint inhibitors: an update
5个月前
已完结
Pembrolizumab + chemotherapy in patients with persistent, recurrent, or metastatic cervical cancer: Subgroup analysis of KEYNOTE-826
6个月前
已完结
KEYNOTE-826: Final overall survival results from a randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer
6个月前
已完结
没有进行任何应助
已找到【积分已退回】
7个月前
标题错误、doi错误
7个月前
重新求助【积分已退回】
2年前
已有资源
2年前
感谢,帮大忙了
2年前
最近帖子
最近评论
没有发布任何帖子
没有发布任何评论